对于可能患上胰管腺癌（PC）的高风险人群（IAR），检测指南正在从大学医院人群中提出。我们在社区医院环境中实施了一项PC筛选标准和协议，资格要求基于个体遗传状态和/或家族病史中是否有PC。纵向测试持续进行，EUS和MRI交替进行。主要目标是分析胰腺状况及其与风险因素的关联。次要目标是评估测试结果和并发症。在93个月的时间里，有102个个体完成了基线EUS测试，其中26个（25%）达到任何胰腺异常结果的定义终点。平均入组时间为40个月，所有达到终点的参与者都继续进行标准的监测。其中两名参与者（1.8%）的终点结果需要手术治疗早期恶性肿瘤。年龄的增加预示着终点发现的可能性。纵向测试的分析表明EUS和MRI的结果可靠。在我们的社区医院人群中，基线EUS能够有效识别大部分病变；随着年龄的增长，异常发现的可能性也增加。EUS和MRI结果没有区别。在高风险人群中开展的PC筛选项目可以在社区环境中成功实施。版权所有©2023 Wolters Kluwer Health，Inc。

Guidelines for testing individuals at risk (IAR) for developing pancreatic duct adenocarcinoma (PC) are being advanced from university hospital populations. We implemented a screen-in criteria and protocol for IAR for PC in our community hospital setting.Eligibility was based on germline status and/or family history of PC. Longitudinal testing continued, alternating between endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI). The primary objective was to analyze pancreatic conditions and their associations with risk factors. The secondary objective was to evaluate the outcomes and complications resulting from testing.Over 93 months, 102 individuals completed baseline EUS, and 26 (25%) met defined endpoints of any abnormal findings in the pancreas. Average enrollment was 40 months, and all participants with endpoints continued standard surveillance. Two participants (1.8%) had endpoint findings requiring surgery for premalignant lesions. Increasing age predicted for endpoint findings. Analysis of longitudinal testing suggested reliability between the EUS and MRI results.In our community hospital population, baseline EUS was effective in identifying the majority of findings; advancing age correlated with a greater chance of abnormalities. No differences were observed between EUS and MRI findings. Screening programs for PC among IAR can be successfully performed in the community setting.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.